Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma

References

• Marchese MJ, Chang CH. Malignant astrocytic gliomas in children. Cancer65, 2771–2778 (1990).
   PubMed Web of Science ®Google Scholar
• Kleihues P, Cavenee WK (Eds). WHO Classification Of Tumors. Tumors of the Nervous System. Pathology and Genetics. Iarc Press, Lyon, France (2000).
   Google Scholar
• Finlay JL, Boyett JM, Yates AJ et al. Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight-drugs-in-1-day regimen. Children’s Cancer Group. J. Clin. Oncol.13, 112–123 (1995).
   PubMed Web of Science ®Google Scholar
• Gilles FH, Brown WD, Leviton A et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors. Cancer88, 1477–1483 (2000).
   PubMed Web of Science ®Google Scholar
• Pollack IF, Boyett JM, Yates AJ et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro-Oncology5, 197–207 (2003).
   PubMed Web of Science ®Google Scholar
• Massimino M, Zucchini N, Frappaz D et al. Toward a SIOP high-grade glioma group: trying a common neuropathology language.Ped. Blood Cancer45, 153 (2005) (Abstract PH 008).
   Google Scholar
• Pollack IF, Finkelstein SD, Woods J et al. Expression of p53 and prognosis in children with malignant gliomas. N. Engl. J. Med.346, 420–427 (2002).
   PubMed Web of Science ®Google Scholar
• Wisoff JH, Boyett JM, Berger MS et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J. Neurosurg.89, 52–59 (1998).
   PubMed Web of Science ®Google Scholar
• Finlay JL, Wisoff JH. The impact of extent of resection in the management of malignant gliomas of childhood. Childs Nerv. Syst.15, 786–788 (1999).
   PubMed Web of Science ®Google Scholar
• Bucci MK, Maity A, Janss AJ et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas. Results from a single center in the magnetic resonance imaging era. Cancer101, 817–824 (2004).
   PubMed Web of Science ®Google Scholar
• Sposto R, Ertel IJ, Jenkin RD et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J. Neurooncol.7, 165–177 (1989).
   PubMed Web of Science ®Google Scholar
• Packer RJ. Re-evaluation of outcome in children with high-grade glioma treated on a Children’s Cancer Study Group CCG-943: a randomized study of radiation alone versus radiation plus adjuvant CCNU, prednisone and vincristine chemotherapy. 7th International Symposium of Pediatric Neuro-oncology. Washington, DC, USA, 15–18 May 1996 (Abstract 34).
   Google Scholar
• Kedar A, Maria BL, Graham-Pole J et al. High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med. Pediatr. Oncol.23, 428–436 (1994).
   PubMedGoogle Scholar
• Kuhl J, Muller HL, Berthold F et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT´88/´89. Klin. Padiatr.210, 227–233 (1998).
   PubMedGoogle Scholar
• Pendergrass TW, Milstein JM, Geyer JR et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J. Clin. Oncol.5, 1221–1231 (1987).
   PubMed Web of Science ®Google Scholar
• Wolff JE, Gnekow AK, Kortmann RD et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer94, 264–271 (2002).
   PubMed Web of Science ®Google Scholar
• Doz F, Neuenschwander S, Bouffet E et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Societe Francaise d'Oncologie Pediatrique. Eur. J. Cancer38, 815–819 (2002).
   PubMedGoogle Scholar
• Massimino M, Gandola L, Casanova M et al. Concomitant chemoradiotherapy for childhood poor-prognosis gliomas. Med. Pediatr. Oncol.34, 147–150 (2000).
   PubMedGoogle Scholar
• Wolff JE, Wagner S, Sindichakis M et al. Simultaneous radiochemotherapy in pediatric patients with high-grade glioma: a Phase I study. Anticancer Res.22, 3569–3572 (2002).
   PubMedGoogle Scholar
• Mulne AF, Ducore JM, Elterman RD et al. Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol.22(1), 41–44 (2000).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch. Neurol.54(5), 554–558 (1997).
   PubMed Web of Science ®Google Scholar
• Wolff JEA, Moelenkamp G, Westphal S et al. Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer89(10), 2131–2137 (2000).
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger C et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone-marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N. Engl. J. Med.14(16), 1165–1173 (1999).
   Google Scholar
• Frei EJ, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am. J. Med.69, 585–594 (1980).
   PubMed Web of Science ®Google Scholar
• Frei E III, Antman K, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumors-prospects. J. Clin. Oncol.7(4), 515–526 (1989).
   PubMed Web of Science ®Google Scholar
• Mason WP, Grovas A, Hapern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnoses malignant brain tumors. J. Clin. Oncol.16(1), 210–221 (1998).
   PubMed Web of Science ®Google Scholar
• Garrè ML, Massimino M, Cefalo G et al. High risk malignant CNS tumors in infants: standard vs myeloablative chemotherapy. The experience of the Italian cooperative study for children < 3 years of age. 10th International Symposium on paediatric Neuro-Oncology. London, UK, 9–12 June 2002. Neuro-Oncol.5(1), 40 (2003).
   Google Scholar
• Hilden JM, Meerbaum S, Burger P et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J. Clin. Oncol.22(14), 2877–2884 (2004).
   PubMed Web of Science ®Google Scholar
• Massimino M, Gandola L, Spreafico F et al. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: a prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.64(4), 1031–1037 (2005).
   PubMedGoogle Scholar
• Grill J, Sainte-Rose C, Jouvet A. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol.6(8), 573–580 (2005).
   PubMed Web of Science ®Google Scholar
• Castro MG, Cowen R, Williamson IK et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol. Ther.98, 71–108 (2003).
   PubMed Web of Science ®Google Scholar
• Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical – and futuristic – perspective. J. Neurooncol.75, 253–266 (2005).
   PubMedGoogle Scholar
• Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res.12, 328–331 (2006).
   PubMed Web of Science ®Google Scholar
• Finlay JL, Goldman S, Wong MC et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J. Clin. Oncol.14, 2495–2503 (1996).
   PubMed Web of Science ®Google Scholar
• Heideman RL, Douglas EC, Krance RA et al. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. J. Clin. Oncol.11, 1458–1465 (1993).
   PubMedGoogle Scholar
• Bouffet E, Mottolese C, Jouvet A et al. Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur. J. Cancer33, 91–95 (1997).
   PubMedGoogle Scholar
• Bouffet E, Raquin M, Doz F et al. Radiotherapy followed by high dose busulfan and thiotepa. A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer88, 685–692 (2000).
   PubMed Web of Science ®Google Scholar
• Finlay JL. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors. Bone Marrow Transplant.18(Suppl.3), S1–S5 (1996).
   Google Scholar
• Graham ML, Herndon JE, Casey JR et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J. Clin. Oncol.15, 1814–1823 (1997).
   PubMed Web of Science ®Google Scholar
• Papadopoulos P, Garvin JH, Fetell M et al. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone Marrow Transplant.22, 661–667 (1998).
   PubMed Web of Science ®Google Scholar
• Chi SN, Gardner SL, Levy AS et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J. Clin. Oncol.22(24), 4881–4887 (2004).
   PubMed Web of Science ®Google Scholar
• Djerassi I, Kim JS, Reggev A. Response of astrocytoma to high-dose methotrexate with citrovorum factor rescue. Cancer55(12), 2741–2747 (1985).
   PubMedGoogle Scholar
• Wagner S, Reinert C, Schmid AJ et al. High-dose methotrexate prior to simultaneous radiochemotherapy in children with malignant high-grade gliomas. Anticancer Res.25, 2583–2588 (2005).
   PubMedGoogle Scholar
• Boiardi A, Silvani A, Croci D, Perego E, Solero CL. Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). Ital. J. Neurol. Sci.13, 583–588 (1992).
   PubMedGoogle Scholar
• Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother. Pharmacol.39(4), 376–379 (1997).
   PubMed Web of Science ®Google Scholar
• Finlay JL, August C, Packer R et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignat gliomas of childhood and adolescence. J. Neurooncol.9, 239–248 (1990).
   PubMed Web of Science ®Google Scholar
• Phillips GL, Wolff SN, Fay JW et al. Intensive 1,3-bis (2-cholroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J. Clin. Oncol.4, 639–645 (1986).
   PubMed Web of Science ®Google Scholar
• Kramer ED, Packer RJ, Ginsberg J et al. Acute neurologic dysfunction associated with high-dose chemotherapy and autologous bone marrow rescue for primary malignant brain tumors. Pediatr. Neurosurg.27, 230–237 (1997).
   PubMedGoogle Scholar
• Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest.19(1), 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Grovas AC, Boyett JM, Lindsley K. Rosenblum M, Yates AJ, Finlay JL. Regimen-related toxicity of myeloabalative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the children’s cancer group. Med. Pediatr. Oncol.33, 83–87 (1999).
   PubMedGoogle Scholar
• Hildebrand J, Badjou R, Collard-Ronge E et al. Treatment of brain gliomas with high dose of CCNU and autologous bone marrow transplantation. Biomedicine32, 71–75 (1980).
   PubMedGoogle Scholar
• Heideman RL, Packer RJ, Reaman GH et al. A Phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer72, 271–275 (1993).
   PubMed Web of Science ®Google Scholar
• Tartaglia RL, Cole DE, Heideman R et al. Chemosensitivity of central nervous system tumors to thiotepa and tepa. Proc. Am. Assos. Cancer Res.30, 1833 (1989).
   Google Scholar
• Allen JC, Helson L. High dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J. Neurosurg.55, 749–756 (1981).
   PubMed Web of Science ®Google Scholar
• McCowage GB, Friedman HS, Moghrabi A. Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. Med. Ped. Oncol.30, 75–80 (1998).
   PubMedGoogle Scholar
• Spreafico F, Scaramuzza D, Gandola L et al. Brain magnetic resonance imaging findings after high-dose chemotherapy and radiotherapy for childhood CNS tumors: a developing world. Proceedings of the 11th International Symposium on Pediatric Neuro-Oncology. Boston, MA, USA, 13–16 June 2004 (Abstract LE34). Neuro-Oncology6(4), (2004).
   Google Scholar
• Fouladi M, Chintagumpala M, Laningham FH et al. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J. Clin. Oncol.22, 4551–4560 (2004).
   PubMed Web of Science ®Google Scholar
• Jakacki R, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med. Pediatr. Oncol.29, 553–559 (1997).
   PubMedGoogle Scholar
• Jakacki R, Siffert J, Jamison C, Velasquez L, Allen JC. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J. Neurooncol.44, 77–83 (1999).
   PubMed Web of Science ®Google Scholar
• Levin VA, Edwards MS, Wright DC et al. Modified procarbazine, CCNU, and vincristine (PCV3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat. Rep.64, 237–241 (1980).
   PubMedGoogle Scholar
• Papadakis V, Dunkel IJ, Cramer LD et al. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervosus system tumors. Bone Marrow Transplant.26, 153–160 (2000).
   PubMedGoogle Scholar
• Massimino M, Gandola L, Luksch R et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro-Oncol.7(1), 41–48 (2005).
   PubMed Web of Science ®Google Scholar
• Dunkel IJ, O’Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr. Neurosurg.24(5), 263–266 (1996).
   PubMedGoogle Scholar
• Packer RJ, Boyett JM, Zimmerman RA et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy: a Children Cancer group Phase I/II trial. Cancer74, 112–123 (1995).
   Google Scholar
• Massimino M, Gandola L, Spreafico F et al. Intrinsic brain stem tumor: changing strategies, changing results? 10th International Symposium on paediatric Neuro-Oncology. London, UK, 9–12 June 2002. Neuro-Oncol.5(1), 51 (2003).
   Google Scholar
• Fagioli F, Biasin E, Mastrodicasa L et al. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer100, 221–221 (2004).
   Google Scholar
• Jakacki RI, Jamison C, Heifetz SA, Caldemeyer K, Hanna M, Sender L. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med. Pediatr. Oncol.29, 553–559 (1997).
   PubMedGoogle Scholar
• Finlay JL, Gardner S, Moreno S et al. Sequential high-dose thiotepa with autologous stem-cells rescue (ASCR) in patients with primary CNS tumors. 12th International Conference on Brain Tumor Research and Therapy. Oxford, UK, 20–23 September 1997 (Abstract) (1997).
   Google Scholar
• Gardner S, Baker D, Belasco J et al. Phase I dose escalation of temozolomide with thiotepa and carboplatin with autologous stem cell rescue (ASCR) in patients with recurrent/refractory central nervosu system (CNS) tumors. International Symposium on Pediatric Neuro-Oncology. Boston, MA, June 13–16 2004. Neuro-Oncol.6, 455 (2004).
   Google Scholar
• Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant.28(6), 551–556 (2001).
   PubMed Web of Science ®Google Scholar
• See SJ, Levin VA, Yung A, Hess KR, Groves MD. 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-Oncol.6, 253–258 (2004).
   PubMedGoogle Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br. J. Cancer91(9), 1656–1662 (2004).
   PubMed Web of Science ®Google Scholar